在心力衰竭中静脉注射铁疗法的常年参数:网细胞危机
Zeynep Kumral1, Hacer Uysal1, Mehmet Birhan Yılmaz1
1Department of Cardiology, Dokuz Eylül University, Faculty of Medicine, İzmir, Türkiye.
Anatolian journal of cardiology
|November 17, 2025
概括
在IV铁疗法后,红细胞计数增加是心力衰竭 (HF) 患者早期的,炎症独立的标志物. 这项测量预测了治疗反应,住院时间缩短,再入院减少,超过了传统的缺铁标志物.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在心力衰竭 (HF) 治疗中,管理并发症至关重要.
- 建议对左心室喷射分数 (LVEF) <50%的HF患者进行静脉注射 (IV) 铁,以解决缺铁问题.
- 传统的标记物,如费里和转蛋白和度 (TSAT),由于炎症和反应延迟而不可靠.
研究的目的:
- 评估HF患者对IV铁疗法的早期反应.
- 评估网细胞计数作为治疗疗效的炎症独立标志物.
- 为了比较网细胞的反应与传统的铁标记物.
主要方法:
- 医院住院的HF患者 (LVEF <50%) 符合IV铁标准被纳入.
- 在入院和治疗后72-120小时内测量了网细胞计数.
- 分析了网红细胞计数与血红蛋白 (Hb) 增加,住院,再入院和死亡率之间的关联.
主要成果:
- 在入院和治疗后,较高的网细胞计数与1个月内Hb增加≥1g/dL相关.
- 网细胞增加≥9%预测显著的Hb增加,具有90%的特异性.
- 网状细胞增加与更短的住院时间和更少的急诊室再入院有关.
结论:
- 在72-120小时内增长的网细胞是高血压中IV铁反应的早期,不依赖炎症的标志物.
- 这种标志物在评估治疗疗效方面优于费里丁和TSAT.
- 基线上升的网细胞可以预测治疗益处,并表明活跃的骨髓反应.
相关概念视频
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
204
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
204
01:22Heart Failure VI: Adjunct Therapies
228
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
228
01:11Renal Failure: Dose Adjustments
396
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
396
01:30Continuous Renal Replacement Therapy
713
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
713
01:20Rheumatic Heart Disease IV: Nursing Management
243
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
243
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
181
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
181